Halaven (eribulin mesylate) / Eisai 
Welcome,         Profile    Billing    Logout  
 71 Diseases   132 Trials   132 Trials   3093 News 


12345678910111213...4243»
  • ||||||||||  NSC305787 / Georgetown University, Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg.
    Journal:  New molecular targets in acute leukemias: cytoskeletal regulatory proteins. (Pubmed Central) -  Oct 29, 2025   
    This review aims to explore the roles of STMN1 and EZR in the pathogenesis of acute leukemias, assessing their potential as therapeutic targets. The goal is to synthesize recent evidence to guide the development of more effective inhibitors, focusing on overcoming therapeutic resistance and tailoring treatments to individual profiles.
  • ||||||||||  Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025. (Pubmed Central) -  Oct 16, 2025   
    Key recommendations include weakly recommending CRT for large (??5?cm) nonmetastatic tumors, preferring drug modification over excision for residual lesions after CRT, and equally considering docetaxel, pazopanib, or eribulin for paclitaxel-resistant cases...Future directions emphasize the need for multicenter registry studies and prospective trials to refine treatment strategies. As advances in genomic medicine and immunotherapy evolve, guideline updates will be essential to ensure optimal patient care.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion, Trial completion date, Trial primary completion date:  EMERALD: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (clinicaltrials.gov) -  Sep 29, 2025   
    P3,  N=446, Completed, 
    Further evaluation of Mec-V, potentially in novel combinations, is justified.Trial Registration NCT03425279Ethics Approval The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/GCP.Abstract 523 Table 1View inline Recruiting --> Completed | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Apr 2022 --> Dec 2024
  • ||||||||||  Abnormal cardiac accumulation on FDG PET due to chemotherapy for breast cancer (e-Poster Area) -  Sep 12, 2025 - Abstract #EANM2025EANM_2153;    
    Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2025 --> Apr 2026 Imaging Evaluation Two nuclear medicine physicians assessed: RV/atrium uptake (abnormal focal)(FIgure.3) Homogeneous LV pattern (diffuse uniform uptake)(Figure.4) Myocardial SUVmax Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis Fisher
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Trial completion, Enrollment change:  PRECIOUS: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (clinicaltrials.gov) -  Sep 10, 2025   
    P3,  N=226, Completed, 
    Imaging Evaluation Two nuclear medicine physicians assessed: RV/atrium uptake (abnormal focal)(FIgure.3) Homogeneous LV pattern (diffuse uniform uptake)(Figure.4) Myocardial SUVmax Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis Fisher Unknown status --> Completed | N=370 --> 226
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
    Trial completion:  A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) -  Aug 28, 2025   
    P2,  N=57, Completed, 
    No ADA against MORAb-202 was detected in postdose samples. Active, not recruiting --> Completed
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal:  KSHV and HPV modulate epithelial-to-mesenchymal transition in oral epithelial cells. (Pubmed Central) -  Aug 15, 2025   
    For the first time, we show that knockdown of vimentin and eribulin treatment can restore E-cadherin and reverse epithelial-to-mesenchymal transition in KSHV- and HPV31-infected oral epithelial cells. These findings fill a gap in our understanding of oncogenesis and metastasis of oral cancers caused by KSHV and HPV31, revealing that vimentin may serve as a potential therapeutic molecular target for KSHV- and HPV-associated oral cancer.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
    P2 data, Journal:  An open-label phase II study: The efficiency and safety of anlotinib?+?eribulin in patients with HER2-negative metastatic breast cancer. (Pubmed Central) -  Aug 11, 2025   
    P2
    The most common treatment-related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2-negative mBC.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Neulasta (pegfilgrastim) / Roche
    Journal:  Aortitis after granulocyte-colony stimulating factor administration: A case report. (Pubmed Central) -  Aug 8, 2025   
    In the present study, the case of a 59-year-old man is presented who received chemotherapy (eribulin) for liver metastases from sacral chordoma and subsequently developed acute aortitis after the administration of G-CSF...After discontinuing the antibiotics, the patient was monitored closely without further treatment. His condition improved within a few days; therefore, it was concluded that aortitis was induced by G-CSF.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal, Real-world evidence:  Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting. (Pubmed Central) -  Aug 7, 2025   
    Overall, the study shows low response rate with manageable toxicity. The findings highlight the need for further focused studies comparing eribulin with existing chemotherapies, especially in the Indian patients with disease heterogeneity and unique genetic makeup.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion date:  Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov) -  Aug 5, 2025   
    P2,  N=13, Active, not recruiting, 
    The addition of ipatasertib to capecitabine or eribulin Trial completion date: May 2025 --> Sep 2025
  • ||||||||||  Serial FDG PET analysis for detection of cardiotoxicity of breast cancer chemotherapy (Room 133+134) -  Aug 1, 2025 - Abstract #EANM2025EANM_584;    
    Trial completion date: May 2025 --> Sep 2025 M-SUR = SUVmean myocardium / SUVmean descending aorta Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis For patients receiving multiple regimens, data compared before/after each regimen Wilcoxon signed-rank test used for comparisons Results Study summary Average observation period: 39 months Average PET scans per patient: 5.0 Total pre/post datasets: 308 Anthracyclines: 34 (17 patients) ICI: 19 (9 patients) HER2 inhibitors: 146 (40 patients) Others: 109 (54 patients) Significant increase in M-SUR after chemotherapy(Figure.4) Anthracyclines: 5.37
  • ||||||||||  cisplatin/vinblastine/SHAO-FA (INT230-6) / Intensity Therap
    Enrollment closed:  A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (clinicaltrials.gov) -  Jul 29, 2025   
    P3,  N=333, Active, not recruiting, 
    M-SUR = SUVmean myocardium / SUVmean descending aorta Classification by chemotherapy regimen(Table.2) Regimens including anthracycline-based agents Examples: AC (doxorubicin + cyclophosphamide), EC (epirubicin + cyclophosphamide) HER2 inhibitors Examples: trastuzumab deruxtecan (Enhertu), trastuzumab (Herceptin), pertuzumab (Perjeta), T-DM1 (Kadcyla) Immune checkpoint inhibitors (ICI) Examples: atezolizumab, pembrolizumab Others eribulin, paclitaxel, docetaxel Analysis For patients receiving multiple regimens, data compared before/after each regimen Wilcoxon signed-rank test used for comparisons Results Study summary Average observation period: 39 months Average PET scans per patient: 5.0 Total pre/post datasets: 308 Anthracyclines: 34 (17 patients) ICI: 19 (9 patients) HER2 inhibitors: 146 (40 patients) Others: 109 (54 patients) Significant increase in M-SUR after chemotherapy(Figure.4) Anthracyclines: 5.37 Recruiting --> Active, not recruiting
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Efficacy and safety of eribulin combined with anlotinib in patients with advanced liposarcoma and leiomyosarcoma (Hall 25) -  Jul 24, 2025 - Abstract #ESMO2025ESMO_3782;    
    Subgroup analysis revealed that LPS pts had better survival benefits than LMS pts, highlighting the need for further exploration of subtype-specific optimization strategies for this combination therapy. Legal entity responsible for the study Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
  • ||||||||||  evorpacept (ALX148) / ALX Oncology
    A single-arm phase 2 study of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer (mBC) (ASPEN-09-03) (Hall 25) -  Jul 24, 2025 - Abstract #ESMO2025ESMO_2295;    
    In 2L+ HER2+ gastric cancer patients, the addition of evo to trastuzumab-ramucirumab-paclitaxel (TRP) demonstrated an objective response rate (ORR) of 41.3% and duration of response (DoR) of 15.7mos compared to the TRP control, ORR 26.6% and DoR 9.1mos (N=127) per investigator assessment (IA)...In a phase 1b study, evo plus zanidatamab (HER2 bispecific antibody) showed promising activity in heavily pretreated patients with centrally confirmed HER2-positive mBC, ORR 55.6%; progression-free survival (PFS) 7.4mos...Trial design The ASPEN-09-03 study is a phase 2 single arm global study evaluating evo in combination with Tras and single agent chemotherapy of physician's choice (vinorelbine, capecitabine, gemcitabine, paclitaxel, or eribulin) in patients with HER2+ mBC previously treated with T-DXd...The primary endpoint in this trial is ORR by independent central review. Key secondary endpoints include ORR by IA, clinical benefit rate, DoR, PFS, overall survival, and safety.